title: Therapeutic modulation of tissue kallikrein expression.
abstract: The kallikrein kinin system has cardioprotective actions and mediates in part the cardioprotection produced by angiotensin converting enzyme inhibitors and angiotensin type 1 receptor blockers. Additional approaches to exploit the cardioprotective effects of the kallikrein kinin system include the administration of tissue kallikrein and kinin receptor agonists. The renin inhibitor aliskiren was recently shown to increase cardiac tissue kallikrein expression and bradykinin levels, and to reduce myocardial ischemia-reperfusion injury by bradykinin B2 receptor- and angiotensin AT2 receptor-mediated mechanisms. Thus, aliskiren represents a prototype drug for the modulation of tissue kallikrein expression for therapeutic benefit.
authors.forename: Duncan J
authors.initials: DJ
authors.lastname: Campbell
mesh_terms: D000577:Amides / Q000494:pharmacology; D000818:Animals; D015195:Drug Design; D005650:Fumarates / Q000494:pharmacology; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects*; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods*; D020840:Tissue Kallikreins / Q000378:metabolism*
chemical_list: D000577:Amides; D005650:Fumarates; C446481:aliskiren; D020840:Tissue Kallikreins